PMID- 35461073
OWN - NLM
STAT- MEDLINE
DCOM- 20220517
LR  - 20220531
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 610
DP  - 2022 Jun 25
TI  - GALNT12 is associated with the malignancy of glioma and promotes glioblastoma 
      multiforme in vitro by activating Akt signaling.
PG  - 99-106
LID - S0006-291X(22)00575-7 [pii]
LID - 10.1016/j.bbrc.2022.04.052 [doi]
AB  - Abnormal expression of mucin-type O-glycosylation has been reported to be 
      associated with a variety of human cancers including gliomas. However, little is 
      known about its contribution to the malignancy of Glioblastoma Multiforme (GBM), 
      the deadliest form of brain tumors. Here, we conducted a detailed analysis of the 
      expression profiles of GALNT gene family, which encode 
      polypeptide-N-acetyl-galactosaminyltransferases (GalNAc-Ts) and are responsible 
      for initiating O-glycans, both in the Cancer Genome Atlas (TCGA) and in the 
      Chinese Glioma Genome Atlas (CGGA) databases. We discovered that GALNT12 is the 
      only member within the GALNT family, whose expression demonstrated significant 
      correlation with a worse prognosis of GBM. Genetic knockdown (KD) and knockout 
      (KO) of GALNT12 in U87 MG, a representative GBM cell line with high GALNT12 
      expression, confirmed that GALNT12 deficiency leads to decreased cell 
      proliferation, migration and invasion. Mechanism study revealed that GALNT12 KD 
      and KO decreased the level of epidermal growth factor (EGF) and consequently 
      attenuated Akt signaling within the cell. In summary, our results indicated that 
      GALNT12 facilitates the malignant characteristics of GBM by influencing the 
      PI3K/Akt/mTOR axis and may serve as a novel prognosis biomarker and a potential 
      therapeutic target of GBM.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - Zheng, Yongjia
AU  - Zheng Y
AD  - School of Pharmaceutical Sciences, National-Local Joint Engineering Laboratory of 
      Druggability and New Drugs Evaluation, Sun Yat-sen University, Guangzhou, 510006, 
      China.
FAU - Liang, Minting
AU  - Liang M
AD  - School of Pharmaceutical Sciences, National-Local Joint Engineering Laboratory of 
      Druggability and New Drugs Evaluation, Sun Yat-sen University, Guangzhou, 510006, 
      China.
FAU - Wang, Bowen
AU  - Wang B
AD  - College of Life Science, Northwest University, Xi'an, 710127, China.
FAU - Kang, Li
AU  - Kang L
AD  - School of Pharmaceutical Sciences, National-Local Joint Engineering Laboratory of 
      Druggability and New Drugs Evaluation, Sun Yat-sen University, Guangzhou, 510006, 
      China.
FAU - Yuan, Yanqiu
AU  - Yuan Y
AD  - School of Pharmaceutical Sciences, National-Local Joint Engineering Laboratory of 
      Druggability and New Drugs Evaluation, Sun Yat-sen University, Guangzhou, 510006, 
      China; Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and 
      Research, Guangzhou, 510990, China.
FAU - Mao, Yang
AU  - Mao Y
AD  - School of Pharmaceutical Sciences, National-Local Joint Engineering Laboratory of 
      Druggability and New Drugs Evaluation, Sun Yat-sen University, Guangzhou, 510006, 
      China; Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and 
      Research, Guangzhou, 510990, China. Electronic address: 
      maoyang3@mail.sysu.edu.cn.
FAU - Wang, Shengjun
AU  - Wang S
AD  - School of Pharmaceutical Sciences, National-Local Joint Engineering Laboratory of 
      Druggability and New Drugs Evaluation, Sun Yat-sen University, Guangzhou, 510006, 
      China; Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and 
      Research, Guangzhou, 510990, China. Electronic address: 
      wangshj35@mail.sysu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20220414
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - EC 2.4.1.- (GALNT12 protein, human)
RN  - EC 2.4.1.- (N-Acetylgalactosaminyltransferases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
MH  - *Brain Neoplasms/pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - *Glioblastoma/pathology
MH  - *Glioma/pathology
MH  - Humans
MH  - *N-Acetylgalactosaminyltransferases/genetics/metabolism
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Proto-Oncogene Proteins c-akt/metabolism
OTO - NOTNLM
OT  - EGF
OT  - GALNT12
OT  - GBM
OT  - Glioblastoma multiforme
OT  - O-glycosylation
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/04/24 06:00
MHDA- 2022/05/18 06:00
CRDT- 2022/04/23 20:13
PHST- 2022/04/02 00:00 [received]
PHST- 2022/04/11 00:00 [revised]
PHST- 2022/04/11 00:00 [accepted]
PHST- 2022/04/24 06:00 [pubmed]
PHST- 2022/05/18 06:00 [medline]
PHST- 2022/04/23 20:13 [entrez]
AID - S0006-291X(22)00575-7 [pii]
AID - 10.1016/j.bbrc.2022.04.052 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2022 Jun 25;610:99-106. doi: 
      10.1016/j.bbrc.2022.04.052. Epub 2022 Apr 14.